Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer
Menée en France dans un contexte de vie réelle à partir de données portant sur 3 653 patientes atteintes d'un cancer du sein métastatique HR+ HER2- ou triple négatif, cette étude de cohorte évalue l'efficacité, du point de vue de la survie globale, et la toxicité du sacituzumab govitécan
Background: Sacituzumab govitecan (SG) was granted early access in France as third-line therapy for metastatic triple-negative breast cancer (mTNBC) and hormone receptor-positive/HER2-negative (HR+/HER2–mBC) metastatic breast cancer. This nationwide cohort study assessed its real-world use and survival outcomes.
Methods: Using the French National Health Data System, we included all patients initiating SG between July 1, 2021, and December 31, 2023, with follow-up until June 30, 2024. Patient demographics, comorbidities, and prior treatments were recorded. Overall survival (OS) and time to treatment discontinuation (TTD) were estimated by Kaplan-Meier methods, and multivariable Cox models identified OS prognostic factors.
Results: 3653 patients were included: 2527 mTNBC and 1,126 HR+/HER2– mBC, with median ages of 58 and 61.5 years. Median OS was 11.0 months (95%CI: 10.4–11.7) for mTNBC and 11.4 months (95% CI: 10.7–12.4) for HR+/HER2–mBC. One-year survival was 47% and 48% and median TTD of 4.3 and 3.5 months, respectively. Poorer OS was independently associated with inpatient SG initiation and liver/digestive metastases. In mTNBC, additional factors included brain metastases, respiratory disease, tobacco-related hospitalisation, multiple metastatic sites, and prior treatments.
Conclusion: The study highlights SG’s clinical relevance and the challenge of translating trial efficacy into real-world outcomes, reinforcing the need for further investigation of tolerability in broader populations.
British Journal of Cancer , article en libre accès, 2026